BR0204001A - Forma de dosagem oral sólida de simeticona - Google Patents

Forma de dosagem oral sólida de simeticona

Info

Publication number
BR0204001A
BR0204001A BR0204001-8A BR0204001A BR0204001A BR 0204001 A BR0204001 A BR 0204001A BR 0204001 A BR0204001 A BR 0204001A BR 0204001 A BR0204001 A BR 0204001A
Authority
BR
Brazil
Prior art keywords
simethicone
dosage form
adsorbent
solid oral
oral dosage
Prior art date
Application number
BR0204001-8A
Other languages
English (en)
Inventor
Christopher E Szymczak
James T Walter
Original Assignee
Johnson & Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson filed Critical Johnson & Johnson
Publication of BR0204001A publication Critical patent/BR0204001A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Abstract

"FORMA DE DOSAGEM ORAL SóLIDA DE SIMETICONA". A presente invenção fornece uma composição para formar uma forma de dosagem sólida prensada que é uma mistura comprimível de fluxo livre de simeticona, um adsorvente, e um agente ativo opcional, onde a relação de peso de simeticona para o adsorvente é pelo menos cerca de 1 : 2,22. Da mesma forma incluídas são as formas de dosagem sólidas feitas de uma mistura comprimível de fluxo livre de simeticona, um adsorvente, e um agente ativo opcional, onde a relação de peso de simeticona para o adsorvente é pelo menos cerca de 1 : 2,22.
BR0204001-8A 2001-09-28 2002-09-30 Forma de dosagem oral sólida de simeticona BR0204001A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/966,441 US7101573B2 (en) 2001-09-28 2001-09-28 Simethicone solid oral dosage form

Publications (1)

Publication Number Publication Date
BR0204001A true BR0204001A (pt) 2003-09-16

Family

ID=25511414

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0204001-8A BR0204001A (pt) 2001-09-28 2002-09-30 Forma de dosagem oral sólida de simeticona

Country Status (18)

Country Link
US (3) US7101573B2 (pt)
EP (1) EP1297825B1 (pt)
AR (1) AR036700A1 (pt)
AT (1) ATE296619T1 (pt)
AU (1) AU2002301259C1 (pt)
BR (1) BR0204001A (pt)
CA (1) CA2405190C (pt)
CO (1) CO5390073A1 (pt)
DE (1) DE60204403T2 (pt)
DK (1) DK1297825T3 (pt)
ES (1) ES2243664T3 (pt)
HU (1) HUP0203176A2 (pt)
MX (1) MXPA02009570A (pt)
NZ (1) NZ521657A (pt)
PL (1) PL204141B1 (pt)
PT (1) PT1297825E (pt)
RU (1) RU2362569C2 (pt)
ZA (1) ZA200207755B (pt)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
US7179488B2 (en) 2001-11-29 2007-02-20 Bob Sherwood Process for co-spray drying liquid herbal extracts with dry silicified MCC
WO2003047551A1 (en) * 2001-11-29 2003-06-12 Penwest Pharmaceutical Company Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
SE0200895D0 (sv) * 2002-03-22 2002-03-22 Astrazeneca Ab New pharmaceutical composition
US7341742B2 (en) * 2002-09-30 2008-03-11 L. Perrigo Company Simethicone containing tablet composition and method
EP1563837A1 (en) * 2004-02-03 2005-08-17 Ferrer Internacional, S.A. Hypocholesterolemic compositions comprising a statin and an antiflatulent agent
RU2384339C2 (ru) * 2004-04-13 2010-03-20 Бёрингер Ингельхайм Интернациональ Гмбх Применение симетикона для предрасположенных к запорам пациентов
CA2565941A1 (en) * 2004-05-04 2005-11-10 Equitech Corporation Improved nsaid composition
US20060024409A1 (en) * 2004-07-29 2006-02-02 Everett Laboratories, Inc. Compositions and methods for nutrition supplementation
US20060024384A1 (en) * 2004-07-29 2006-02-02 Giordano John A Compositions and methods for nutrition supplementation
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
BRPI0608928A2 (pt) * 2005-03-24 2010-02-17 Daiichi Sankyo Co Ltd composição farmacêutica
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
BRPI0615607A2 (pt) * 2005-08-30 2011-05-24 Lek Pharmaceuticals composição farmacêutica compreendendo perindopril ou seus sais
KR101252635B1 (ko) * 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
US20080015260A1 (en) * 2006-07-13 2008-01-17 Kiel Laboratories, Inc. Pharmaceutical compositions having improved stability and methods for preparation and use
US20080038410A1 (en) * 2006-08-18 2008-02-14 Everett Laboratories, Inc. Compositions and methods for nutrition supplementation
WO2008057802A2 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
WO2008056200A1 (en) * 2006-11-10 2008-05-15 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of simethicone
KR20090088913A (ko) 2006-11-21 2009-08-20 맥네일-피피씨, 인코포레이티드 개질된 방출형 진통 현탁제
US9833510B2 (en) * 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
US20090004248A1 (en) * 2007-06-29 2009-01-01 Frank Bunick Dual portion dosage lozenge form
WO2009105568A1 (en) 2008-02-20 2009-08-27 The Curators Of The University Of Missouri Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) * 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
PL2318035T3 (pl) 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
CN105031628B (zh) 2009-01-06 2020-10-02 加尔纳根有限责任公司 治疗或预防大肠杆菌导致的经口感染的组合物和方法
KR20170005192A (ko) 2009-01-06 2017-01-11 큐어론 엘엘씨 스타필로코쿠스 아우레우스 감염의 치료 또는 예방 및 표면 상의 스타필로코쿠스 아우레우스의 박멸 또는 감소를 위한 조성물 및 방법
US20100247586A1 (en) * 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
JP5410819B2 (ja) * 2009-04-09 2014-02-05 ライオン株式会社 木クレオソート含有固形製剤
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
AU2012245287B2 (en) 2011-04-21 2017-04-13 Curemark, Llc Compounds for the treatment of neuropsychiatric disorders
CA2835293C (en) 2011-06-08 2020-08-18 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
ES2613667T3 (es) 2011-09-08 2017-05-25 Mereo Biopharma 2 Limited Composiciones farmacéuticas que comprenden un inhibidor de aromatasa
AU2012327212B2 (en) * 2011-10-27 2016-05-12 Rite-Prep Pty Ltd Electrolyte purgatives
ITMI20112221A1 (it) * 2011-12-05 2013-06-06 Altergon Sa Formulazioni stabili in capsule di gelatina molle di antiaggreganti piastrinici, acidi grassi omega-3 e amilosio
RU2602745C2 (ru) 2011-12-14 2016-11-20 Дисфар Интернэшнл Б.В. Состав с симетиконом
RU2491941C1 (ru) * 2011-12-27 2013-09-10 Вадим Алексеевич Козловский Композиционный энтеросорбент
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
MA41620A (fr) 2015-05-14 2018-01-09 Abdi Ibrahim Ilac Sanayi Ve Ticaret A S Composition pharmaceutique comprenant de la siméthicone et de l'otilonium
JP6724537B2 (ja) * 2015-05-26 2020-07-15 大正製薬株式会社 固形製剤
WO2016201119A1 (en) * 2015-06-09 2016-12-15 J. Rettenmaier & Söhne Gmbh + Co Kg Excipient and oral solid dosage forms for oily drugs
US10166185B2 (en) * 2015-06-09 2019-01-01 J. Rettenmaier & Söhne Gmbh + Co Kg Excipient and oral solid dosage forms for oily drugs
EP3294269A1 (en) 2015-06-12 2018-03-21 Santa Farma Ilaç Sanayi A.S. Oral pharmaceutical composition comprising otilonium bromide and simethicone with certain bulk density and improved dissolution characteristics
WO2017062997A1 (en) 2015-10-09 2017-04-13 Reckitt Benckiser Llc Pharmaceutical formulation
MX2016016587A (es) * 2016-12-14 2018-06-13 Rhein Siegfried Sa De Cv Composicion mejorada de lansoprazol y simeticona y procesos para prepararla.
US10722472B2 (en) 2017-09-29 2020-07-28 Johnson & Johnson Consumer Inc. Solid simethicone particles and dosage form thereof
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
FR3117780B1 (fr) * 2020-12-22 2024-04-05 Oreal Composition anhydre sous forme de poudre compacte comprenant un sel de magnesium et de la cellulose microcristalline

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56169622A (en) * 1980-06-03 1981-12-26 Kissei Pharmaceut Co Ltd Method of making solid preparation from oily substance
US4744987A (en) * 1985-03-08 1988-05-17 Fmc Corporation Coprocessed microcrystalline cellulose and calcium carbonate composition and its preparation
US4851226A (en) 1987-11-16 1989-07-25 Mcneil Consumer Products Company Chewable medicament tablet containing means for taste masking
US4906478A (en) 1988-12-12 1990-03-06 Valentine Enterprises, Inc. Simethicone/calcium silicate composition
US5275822A (en) 1989-10-19 1994-01-04 Valentine Enterprises, Inc. Defoaming composition
US5073384A (en) 1989-10-19 1991-12-17 Valentine Enterprises, Inc. Maltodextrin/defoaming composition combinate
IN171919B (pt) 1989-11-01 1993-02-06 Mcneil Ppc Inc
US5075114A (en) 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
CA2068402C (en) 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
JP3177707B2 (ja) 1991-10-08 2001-06-18 堀井薬品工業株式会社 消化管内ガス除去剤
RU2123863C1 (ru) * 1992-04-30 1998-12-27 Шеринг Корпорейшн Содержащая гидратированный цефтибутен порошковая антибактериальная композиция, предназначенная для орального использования в виде суспензии
GR1002332B (el) * 1992-05-21 1996-05-16 Mcneil-Ppc Inc. Νεες φαρμακευτικες συνθεσεις που περιεχουν σιμεθεικονη.
CA2110313C (en) * 1992-12-01 2004-10-26 Edward John Roche Pharmaceutical compositions containing a guanidinothiazole compound and antacids
FR2705966B1 (fr) 1993-06-04 1995-08-25 Dow Corning Sa Compositions antimousse utiles notamment pour le traitement de troubles gastriques.
EP0725630A1 (en) * 1993-10-28 1996-08-14 The Procter & Gamble Company Fast dissolving dosage forms containing magnesium aluminum silicate and multiple active ingredients
EP0659403B1 (en) 1993-12-15 2001-03-14 National Starch and Chemical Investment Holding Corporation Use of oil adsorbent natural polymer for cosmetic and pharmaceutical applications
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
IL139728A (en) * 1995-01-09 2003-06-24 Penwest Pharmaceuticals Compan Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient
US6106865A (en) * 1995-01-09 2000-08-22 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
US6190696B1 (en) * 1998-06-08 2001-02-20 Pieter J. Groenewoud Stabilized thyroxine medications
US6126967A (en) 1998-09-03 2000-10-03 Ascent Pediatrics Extended release acetaminophen particles
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form

Also Published As

Publication number Publication date
AR036700A1 (es) 2004-09-29
EP1297825B1 (en) 2005-06-01
RU2002125821A (ru) 2004-03-27
US7101573B2 (en) 2006-09-05
DE60204403T2 (de) 2006-05-04
PL204141B1 (pl) 2009-12-31
RU2362569C2 (ru) 2009-07-27
CA2405190C (en) 2010-11-09
US20070196468A1 (en) 2007-08-23
ATE296619T1 (de) 2005-06-15
PT1297825E (pt) 2005-08-31
CO5390073A1 (es) 2004-04-30
AU2002301259C1 (en) 2009-07-23
US20030091624A1 (en) 2003-05-15
PL356358A1 (en) 2003-04-07
HUP0203176A2 (hu) 2004-07-28
DE60204403D1 (de) 2005-07-07
AU2002301259B2 (en) 2009-01-22
EP1297825A1 (en) 2003-04-02
NZ521657A (en) 2004-05-28
ZA200207755B (en) 2004-03-26
CA2405190A1 (en) 2003-03-28
DK1297825T3 (da) 2005-09-26
HU0203176D0 (pt) 2002-11-28
ES2243664T3 (es) 2005-12-01
US20100135982A1 (en) 2010-06-03
MXPA02009570A (es) 2004-07-30
US7691409B2 (en) 2010-04-06

Similar Documents

Publication Publication Date Title
BR0204001A (pt) Forma de dosagem oral sólida de simeticona
BRPI0316532B8 (pt) composições farmacêuticas compreendendo uma droga básica ou ácida, um tensoativo, e um ácido ou base solúvel em água fisiologicamente tolerável
BRPI0415121A (pt) material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida
HN2001000008A (es) Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
CL2008000762A1 (es) Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la psoriasis, diabetes, artritis reumatoide, entre otras enfermedades ( divisional solicitud 1147-02).
BR0215148A (pt) Composições farmacêuticas de agonista parcial 5ht4
BR0208643A (pt) Composição para tratamento de cabelos
BR0215193A (pt) Formulações de azitromicina diretamente compressìveis
BRPI0409342A (pt) pelìcula de gel termorreversìvel homogênea, cápsulas moles, processos para fabricar as pelìculas de gel e para fabricar cápsulas moles contendo as pelìculas de gel, e, forma sólida
BRPI0414876A (pt) compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos
BRPI0516718B8 (pt) formulação de liberação modificada de ibuprofeno fornecendo liberação imediata e prolongada do fármaco
BR0317392A (pt) Formulação não-higroscópica incluindo uma droga higroscópica
BR0108238A (pt) Composições cosméticas contendo pelo menos um hetero polìmero e pelo menos uma resina de silicone de formação de pelìcula e métodos de empregá-las
UY28931A1 (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
BR0107027A (pt) Composição cosmética ou farmacêutica que se apresenta em forma sólida compreendendo bis-acilamidas
UY29096A1 (es) Compuestos de benzamida
BR0107564A (pt) Composição de gliburida
BR0202491A (pt) Forma de dosagem de núcleo macio, de revestimento frágil
BR0111868A (pt) Composições farmacêuticas
BR0212353A (pt) Composto, composição farmacêutica, e, uso de um composto
BR0208813A (pt) Composições contendo imidazotriazinona para a aplicação nasal
BR0101492A (pt) Misturas de pelo menos um enchedor e compostosde organossilìcio, processo para sua preparação eseu uso
SV2006002122A (es) Prodrogas de estriol y estetrol ref. p-sv-78.343/msu
BR9912706A (pt) Composições farmacêuticas contendo ibuprofeno e domperidona
CL2004001843A1 (es) Combinacion de (a) al menos un derivado 2,5-dihidrobencenosulfonico, como el dobeilato calcico, etamsilato y persilato, y (b) al menos un modulador de los canales de potasio, composicion farmaceutica que la contiene y uso como medicamento en profilax

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Free format text: PARA.INT.CI.A61K 9/20, A61K 9/48, A61K 31/80, A61P 1/00

Ipc: A61K 9/20 (2011.01), A61K 9/48 (2011.01), A61K 31/

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8, 13 E 25 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]